MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

27.69 -0.18

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.28

Massimo

28.02

Metriche Chiave

By Trading Economics

Entrata

-28M

22M

Vendite

4.3M

244M

P/E

Media del settore

9.926

56.063

Margine di Profitto

9.224

Dipendenti

293

EBITDA

-22M

52M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+48.7% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8.3M

1.6B

Apertura precedente

27.87

Chiusura precedente

27.69

Notizie sul Sentiment di mercato

By Acuity

43%

57%

153 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 apr 2026, 23:17 UTC

Utili

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Azioni calde

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

I principali Market Mover

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

I principali Market Mover

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Principali Notizie su Eventi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

I principali Market Mover

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Discorsi di Mercato

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Discorsi di Mercato

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Discorsi di Mercato

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Discorsi di Mercato

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Discorsi di Mercato

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Discorsi di Mercato

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Discorsi di Mercato

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisizioni, Fusioni, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisizioni, Fusioni, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Discorsi di Mercato

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Utili

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

48.7% in crescita

Previsioni per 12 mesi

Media 41.25 USD  48.7%

Alto 62 USD

Basso 25 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

153 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat